Fluorangiography is a technique for examining the circulation of the retina. It consists in using a fluorescent dye and a specialized camera to take pictures of the retina; it lasts for about 5 minutes. Fluorangiography is especially useful in case of diabetic retinopathy or retinal thrombosis. It enlighten ischemic areas (scarcely vascularized) and neovessels (abnormal vessels that appear to try reactivate circulation) in an initial phase, offering the possibility to perform a precise laser treatment.
Patients affected by advanced diabetes, may need to repeat fluorangiography once a year or more. Dr. Badalà periodically organizes screenings for diabetic retinopathy with the exam of the bottom of the eye and fluorangiography in Milan and Catania.
Nella retinopatia diabetica o nella retinopatia da trombosi retinicalo scopo del trattamento laser della retina è quello di ridurre il consumo di ossigeno del tessuto retinico, per adattarlo alla situazione circolatoria deficitaria; questo è in pratica ottenuto distruggendo selettivamente le aree meno nobili della retina.Questo può tradursi in un leggero calo della vista, e/o del campo visivo soprattutto in condizioni di semioscurità.
Il laser può poi essere eseguito dopo rottura della retina per cucire la retina circostante mediante la creazione di un cicatrice.
Vitrectomy‘s risks and complications are linked to the reason why the surgery is performed.
Vitrectomy for macular pucker or performed for an emovitreum, usually achieve great results. Viceversa, in case of retinal detachment, vision recovery can be incomplete or happen after a long time.
Vitrectomy usually stimulates cataract formation. The possibility of serious complications can be limited by a good preparation, a prudent surgical procedure and a careful post-op control.
Main risks happen when vitrectomy is linked by the use of silicone oil that is injected inside the eye to sustain the retina and is removed 2 or 3 months after surgery.
Right now there are experimental procedures that may bring great results but unfortunately only in long time periods and for specific cases. The most promising project is called ARGUS II Retinal Implant, by the american company Second Sight.
One of the most important retinopathy centers for this device is the Philadelphia Wills Eye Institute, where Dr. Badalà worked; he is now ophthalmologist in Milan and Catania and has a wide experience on this very device.